LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following open letter to STAAR stockhol…
Author: Business Wire
Future Forward Labs Appoints Dr. Delia DeBuc as Applied Science Mentor to Advance Applied Physics and Biomedical Innovation
SEATTLE–(BUSINESS WIRE)– #highschool–Future Forward Labs today announced the appointment of Dr. Delia DeBuc as STEM Mentor – Applied Physics and Biomedical Science. Dr. DeBuc brings more than 20 years of multidisciplinary research, scientific leader…
Dompé verabreicht Isocyclosporin an erste Patienten einer Phase-3-Studie in Europa und den USA für die Indikation atopische Keratokonjunktivitis
MAILAND und SAN MATEO, Kalifornien, USA–(BUSINESS WIRE)–Dompé, ein führendes Biopharmaunternehmen mit Niederlassungen in Italien und den USA, meldete die Aufnahme der ersten Patienten in eine Phase-3-Studie zu Isocyclosporin für die Behandlung von at…
Dompé behandelt eerste patiënten in Europa en de VS in fase 3-onderzoek naar isocyclosporine voor atopische keratoconjunctivitis
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft aangekondigd dat de eerste patiënten zijn ingeschreven voor een fase 3-onderzoek naar isocyclosporine voor de beha…
Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
HONG KONG–(BUSINESS WIRE)–Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today re…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé somministra le dosi ai primi pazienti in Europa e negli Stati Uniti nello studio di fase 3 sull'isociclosporina per la cheratocongiuntivite atopica
MILANO e SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato l’arruolamento dei primi pazienti in uno studio di fase 3 sulla isociclosporina per il trattament…
Dompé administre les premières doses à des patients en Europe et aux États-Unis dans le cadre d'une étude de Phase 3 sur l'isocyclosporine pour traiter la kératoconjonctivite atopique
MILAN et SAN MATEO, Californie–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, annonce que les premiers patients ont été admis dans une étude de Phase 3 sur l’isociclosporine sur le traiteme…
Dompé inicia en Europa y Estados Unidos un estudio de fase 3 de isociclosporina en pacientes con queratoconjuntivitis atópica
MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…
Dompé inicia en Europa y Estados Unidos un estudio de fase 3 de isociclosporina en pacientes con queratoconjuntivitis atópica
MILÁN y SAN MATEO, California–(BUSINESS WIRE)–Dompé, empresa biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado el inicio de la inclusión de los primeros pacientes en un estudio de fase 3 de isociclosporina para el tratami…
Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported that independent industry analysts have r…
Tenpoint Therapeutics, Ltd. to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
LONDON & SEATTLE–(BUSINESS WIRE)–Tenpoint Therapeutics, Ltd., a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive …
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that i…
Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé advances a novel, dual-inhibitor into Phase 3 for AKC, a chronic inflammatory eye disease with no FDA-approved treatment options.
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food an…
Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that leading independent proxy…
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating…
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,…